|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||352.40 - 361.50|
|52 Week Range||268.13 - 438.85|
|PE Ratio (TTM)||39.97|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||353.22|
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, July 13, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the companies' proposed biosimilar trastuzumab. The committee voted 16-0 in support of eligible indications of the reference product, Herceptin®, which include HER2-positive breast cancer in the metastatic and adjuvant settings.
Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its biosimilar copy of Amgen Inc's blockbuster treatment, Neulasta, which is used to fight infections in cancer patients. Shares of Coherus tumbled 30 percent to $14.47 in morning trading, while Amgen's shares were up slightly at $164.19.
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the presentation of new data from the insulin glargine clinical program, including the INSTRIDE studies at the American Diabetes Association's 77th Scientific Sessions in San Diego. The studies confirmed the efficacy, safety and immunogenicity of MYL-1501D, insulin glargine, in comparison to Lantus® in patients with Type 1 and Type 2 diabetes.